Title: Establishing of a risk prediction model for metabolic dysfunction associated steatotic liver
disease: a retrospective cohort study
Version: 1 Date: 08 Oct 2024
Reviewer:  Maria Eugenia Icaza-Chávez
Reviewer's report:
I find this study very important. The current parameters accepted now a days for selecting wich
patients should be submited to further study to detect those at risk of advanced liver fibrosis are
not ideal (like FIB-4 and NAFLD score).
I have some comments:
A)   What kind of hormone use was an exclusion criteria? Levothyroxine, estradiol?
B) So during a maximum of 4 years follow up, almost 20% of individuals developed MASLD?
The prevalence of MASLD in general population has been described to be 30 to 40%, so it seems
quite high that a check up population develops this condition in  4 years. Just asking.
C) Before stating that  the model effectively assist clinical physicians in predicting and
evaluating the probability of MASLD incidence, they have to be tested in other populations
Title: Establishing of a risk prediction model for metabolic dysfunction associated steatotic liver
disease: a retrospective cohort study
Version: 1 Date: 08 Oct 2024
Reviewer:  Maria Eugenia Icaza-Chávez
Reviewer's report:
I find this study very important. The current parameters accepted now a days for selecting wich
patients should be submited to further study to detect those at risk of advanced liver fibrosis are
not ideal (like FIB-4 and NAFLD score).
I have some comments:
A)   What kind of hormone use was an exclusion criteria? Levothyroxine, estradiol?
B) So during a maximum of 4 years follow up, almost 20% of individuals developed MASLD?
The prevalence of MASLD in general population has been described to be 30 to 40%, so it seems
quite high that a check up population develops this condition in  4 years. Just asking.
C) Before stating that  the model effectively assist clinical physicians in predicting and
evaluating the probability of MASLD incidence, they have to be tested in other populations
Please review this paper.
user
Title: Establishing of a risk prediction model for metabolic dysfunction associated steatotic liver
disease: a retrospective cohort study
Version: 1 Date: 08 Oct 2024
Reviewer:  Maria Eugenia Icaza-Chávez
Reviewer's report:
I find this study very important. The current parameters accepted now a days for selecting wich
patients should be submited to further study to detect those at risk of advanced liver fibrosis are
not ideal (like FIB-4 and NAFLD score).
I have some comments:
A)   What kind of hormone use was an exclusion criteria? Levothyroxine, estradiol?
B) So during a maximum of 4 years follow up, almost 20% of individuals developed MASLD?
The prevalence of MASLD in general population has been described to be 30 to 40%, so it seems
quite high that a check up population develops this condition in  4 years. Just asking.
C) Before stating that  the model effectively assist clinical physicians in predicting and
evaluating the probability of MASLD incidence, they have to be tested in other populations
assistant